BMY.BA
Bristol-Myers Squibb Company News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1,
"returned": 1,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "b0d78c4c-fdf3-48ee-a124-f9e7fbcfe4dc",
"title": "Should You Pick Bristol Myers Squibb Stock At $45?",
"description": "Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates.",
"keywords": "Bristol Myers Squibb Stock, Bristol Myers Squibb, S&P 500, bmy stock, bmy revenue, bmy valuation, bmy q1, eliquis",
"snippet": "GERMANY - 2024/03/03: In this photo illustration, the Bristol-Myers Squibb Company logo is seen ... [+] displayed on a tablet. (Photo Illustration by Igor Golov...",
"url": "https://www.forbes.com/sites/greatspeculations/2024/05/01/should-you-pick-bristol-myers-squibb-stock-at-45/",
"image_url": "https://imageio.forbes.com/specials-images/imageserve/6631a90e7662a93a9dbc02f1/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
"language": "en",
"published_at": "2024-05-01T11:00:00.000000Z",
"source": "forbes.com",
"relevance_score": null,
"entities": [
{
"symbol": "BMY.BA",
"name": "Bristol-Myers Squibb Company",
"exchange": null,
"exchange_long": null,
"country": "ar",
"type": "equity",
"industry": "Healthcare",
"match_score": 121.19171,
"sentiment_score": 0.200083,
"highlights": [
{
"highlight": "GERMANY - 2024/03/03: In this photo illustration, the <em>Bristol</em>-<em>Myers</em> <em>Squibb</em> <em>Company</em> logo is seen ... [+] displayed on a tablet.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images\n\n<em>Bristol</em> <em>Myers</em> <em>Squibb</em> <em>Bristol</em> <em>Myers</em> <em>Squibb</em> (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "A slight decline in valuation multiple for <em>Bristol</em> <em>Myers</em> <em>Squibb</em> seems justified in our view, given a significant expected dip in 2024 earnings.\n\nBristol Myers Squibb’s revenue of $11.9 billion in Q1 was up 5% y-o-y, as lower sales of Revlimid were more than offset by higher sales of Eliquis, Reblozyl and Opdualag.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Bristol</em> <em>Myers</em> <em>Squibb</em> recorded a one-time charge of $12.1 billion for the acquisition of Karuna. This resulted in the company’s bottom-line plunging to a loss of $4.40 on an adjusted basis, compared to earnings of $2.05 per share in the prior-year quarter.",
"sentiment": -0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "Although there are near-term headwinds for <em>Bristol</em> <em>Myers</em> <em>Squibb</em>, its long-term growth prospects look robust, with its newer drugs expected to turn into blockbuster drugs over the coming years. The company should be able to expand its pipeline through its new acquisitions, including Mirati, Karuna, and RayzeBio.",
"sentiment": 0.9081,
"highlighted_in": "main_text"
},
{
"highlight": "Should You Pick <em>Bristol</em> <em>Myers</em> <em>Squibb</em> Stock At $45?",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "BMY.BA",
"total_documents": 1,
"sentiment_avg": 0.20008300244808197
}
]
}
Other details
Exchange
- Buenos Aires Stock Exchange
- equity
- Healthcare
- ar